AltPep Corporation revealed new preclinical findings at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), showing that its lead therapeutic candidate SOBIN-AD (Soluble Oligomer Binding INhibitor) improved cognitive and pathological markers in animal models of Alzheimer’s disease (AD).
AltPep reported that SOBIN-AD treatment enhanced memory in both symptomatic and asymptomatic transgenic AD mice. For asymptomatic mice, long-term dosing was associated with reduced formation of amyloid-β plaques and preservation of synaptophysin — a key protein for neuronal signaling — at advanced age. In symptomatic mice, SOBIN-AD also led to cognitive improvements when administered after onset of impairment.
According to AltPep, SOBIN-AD acts through a novel mechanism: it selectively binds toxic “α-sheet” oligomers—believed to be early triggers of amyloid diseases—promotes their clearance, and enhances phagocytosis by microglial cells. The results build on data the company previously presented at another conference earlier in 2025, where SOBIN-AD was shown to inhibit plaque formation and improve memory in pre-symptomatic mice after extended treatment.
AltPep emphasized that these findings support SOBIN-AD’s potential as a disease-modifying therapy for early and perhaps later stages of Alzheimer’s disease.
